glp-1 ignite patches Patches': Do the Products Influencers Are Selling Work? GLP-1 Companion System
Description
He hoped to sell higher volumes of obesity and diabetes drugs over the coming years, saying: We are seeing a volume response to lower prices. He pointed to Novos agreement with the Trump administration to cut prices heavily, from more than $1,000 a month (730) to an average price of $350 (255), and the patent expiry of semaglutide, the main ingredient of its obesity and diabetes drugs, in several countries including India
Sales have been robust, with 77% of Vital Pursuit purchases coming from households where no one is using GLP-1 drugs
Lancet Diabetes Endocrinol 10(6):393406
This policy shift increases the likelihood that clinicians will need to document comorbid indications such as type 2 diabetes or cardiovascular disease to justify continued prescribing under covered diagnoses
BMJ 339(nov24 1):b4567 Titze J (2015) A different view on sodium balance
